膀胱癌表皮生长因子受体的免疫组化研究  

Immunohistochemical study on EGFR in human bladder carciuoma

作　　者：习小庆[1] 葛根[1] 孙锡林[1] 黄国华[1] 肖湘[1] 熊华淇 张文昌[1] 

机构地区：[1]江西医学院第二附属医院泌尿外科,江西医学院病理教研室,江西医学院第二附属医院病理科

出　　处：《中华泌尿外科杂志》1995年第1期21-23,共3页Chinese Journal of Urology

摘　　要：用免疫组化ＡＢＣ法对５６例膀胱移行细胞癌和４例正常膀胱组织表皮生长因子受体进行检测。结果表明：５５．４％的膀胱肿瘤显示阳性（３１／５６），正常膀胱组织均为阴性反应。尽管膀胱肿瘤的表皮生长因子受体表达与肿瘤分级无明显关系，但Ｇ３的表达率（７３．３％）明显高于Ｇ２（５６％）和Ｇ１（３７．５％）。其阳性表达者预后较差。浸润性肿瘤的阳性表达率明显高于表浅性肿瘤（Ｐ＜０．０５），且表浅性肿瘤阳性表达者肿瘤易扩展。提示表皮生长因子受体可能为评估膀胱肿瘤浸润程度及预后的一个指标。Detection of expression of epidermal growth factor receptor (EGFR) was carried out in 56 human bladder carcinomas and 4 normal bladder tissues using immunohistochemical approach. Positive staining was found in 55.4%. of transitional cell carcinomas ( 31/56),but in none of normal tissues. Although on statistical association was observed between expression of EGFR and histological grade of the tumor, the incidence of expression for EGFR was higher in G3 (73.3%) than in G2 (56 %) and G1 ( 37. 5 %) and the incidence of expression in invasive tumors was significantly higher than the superficial ones (P <0. 05). Cases of superficial tumors with positive staining for EGFR seemed to spread more frequently. EGFR may therefore be applicable as a tumor marker for the evaluation of invasiveness and prognosis of bladder carcinoma.

关 键 词：膀胱肿瘤 癌 免疫化学 

分 类 号：R737.140.3[医药卫生—肿瘤]